Complete responses of long duration and partial responses with great tumor reduction rates were achieved by these patients, with the more marked favorable overall results attained by patients whose tumors overexpressed HER2, as expected from prior studies with patients treated with chemotherapy associated with anti HER-2/neu monoclonal antibodies, preferably with trastuzumab and pertuzumab combined58. This evidence concerns the gene ERBB2 and neoplasm.